Fresenius Medical Care Unveils Xenios 2.0: Next-Generation ECLS System with Advanced Safety and Connectivity Features

Fresenius Medical Care Unveils Xenios 2.0: Next-Generation ECLS System with Advanced Safety and Connectivity Features

(IN BRIEF) Fresenius Medical Care’s subsidiary, Xenios AG, has launched Xenios 2.0, a new system for extracorporeal life support (ECLS) that serves patients from neonates to adults. Approved under the new Medical Device Regulation (MDR), Xenios 2.0 offers advanced safety features, simplified user interfaces, and seamless connectivity for better integration with patient monitoring systems. The system ensures reliable performance with backup systems and provides a more efficient, user-friendly experience for healthcare professionals. Xenios 2.0 is expected to enhance ECLS treatments across the European market.

(PRESS RELEASE) HEILBRONN, 15-Oct-2024 — /EuropaWire/ — Fresenius Medical Care’s heart and lung subsidiary, Xenios AG, has launched Xenios 2.0, a next-generation system for extracorporeal life support (ECLS). This new system is designed to deliver high-performance ECLS treatments for patients of all ages, from neonates to adults, and has been approved under the strict Medical Device Regulation (MDR) standards.

Xenios 2.0 prioritizes safety, simplicity, and connectivity. The device is equipped with advanced safety features, including integrated pressure sensors, intelligent alarm systems, and backup systems to ensure continued operation even during technical issues or power failures. Its simplified user interface helps reduce errors, while step-by-step instructions and trend displays make it user-friendly and efficient, even for less experienced personnel.

The system’s connectivity capabilities allow it to integrate seamlessly with patient monitoring systems and electronic medical records, significantly reducing the workload for healthcare professionals by automating data transfer and documentation.

According to Dr. Benjamin Waldmann, CEO of Xenios AG, “Xenios 2.0 represents a significant advancement in ECLS treatments, offering enhanced safety features that will greatly benefit physicians and caregivers.”

Xenios 2.0 has been approved for the European CE market and will be available soon.

About Fresenius Medical Care:
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,757 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 311,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

About Xenios:
At Xenios, a Fresenius Medical Care company, we offer extracorporeal membrane oxygenation (ECMO) solutions that combine cardiac and pulmonary support on one single technological platform. The ECMO device supports gas exchange in the lungs and the cardiovascular system to increase the chance of survival in critically ill patients. Physicians may gain vital treatment time during diagnosis and therapy.

Xenios AG is a part of Fresenius Medical Care, the world’s leading provider of products and services for people with renal diseases. We are complementing Fresenius Medical Care’s product portfolio in the field of intensive care and are continuing to shape the future of extracorporeal multi-organ support.
In our daily work, we share a passion for helping people. For patients. Worldwide. Every day.

For more information visit the Company’s website at: www.xenios-ag.com

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media Contact:

Tel. +49 (0) 6172 – 609 0
media(at)freseniusmedicalcare.com

SOURCE: Fresenius SE & Co. KGaA